Latest Healthcare Research Reports

Tag: short bowel syndrome market

  • Short Bowel Syndrome Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Short Bowel Syndrome Market Opportunities Are Emerging Beyond Traditional Growth Areas

    Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

    Short Bowel Syndrome Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

    The market for short bowel syndrome has experienced substantial expansion lately, projecting a rise from $3.08 billion in 2025 to $3.53 billion in 2026, fueled by a compound annual growth rate (CAGR) of 14.6%. This notable increase during the past period is linked to several key factors, including a greater incidence of short bowel syndrome, the limited therapeutic avenues previously available, a prevalent dependency on parenteral nutrition, an uptick in gastrointestinal surgical procedures, and heightened awareness within healthcare facilities.

    The short bowel syndrome market is poised for substantial expansion in the approaching years, projecting a valuation of $6.02 billion by 2030, fueled by a compound annual growth rate of 14.2%. This upward trajectory during the forecasted period is anticipated to be driven by advancements in innovative treatments, greater access to home-based infusion services, the implementation of tailored therapeutic strategies, the incorporation of microbiome-based therapies, and an increase in clinical investigations focused on short bowel syndrome interventions. Key developments expected to shape the market in the coming years encompass an escalation in parenteral nutrition solutions, advancements in intestinal rehabilitation therapies, the adoption of new surgical procedures, a heightened emphasis on modulating the gut microbiome, and the broadening of patient advocacy and support initiatives.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    Short Bowel Syndrome Market Growth Factors: Which Forces Are Supporting Market Expansion?

    A surge in gastrointestinal ailments is anticipated to fuel the expansion of the short bowel syndrome market. These extensive digestive tract conditions, encompassing issues with the stomach, intestines, liver, and pancreas, frequently result in compromised digestion and nutrient assimilation. The rising incidence of these ailments is primarily attributed to detrimental dietary patterns that compromise gut integrity and foster inflammation. Such gastrointestinal conditions can precipitate short bowel syndrome by necessitating the surgical excision of compromised intestinal sections, thereby diminishing the body’s capacity for absorption. Illustratively, in September 2023, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre in Canada reported that inflammatory bowel disease affects over 320,000 individuals in that country, a prevalence rate of 825 per 100,000 in 2023. With an anticipated annual increase of 2.44%, the number of Canadians living with IBD is projected to reach 470,000, or 1.1% of the population, by 2035. Consequently, the escalating occurrence of gastrointestinal diseases is a significant factor propelling the short bowel syndrome market forward.

    Short Bowel Syndrome Market Segment Breakdown: Which Categories Generate The Most Revenue?

    The short bowel syndrome market covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

    2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

    3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

    4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine, Intravenous Glutamine

    Short Bowel Syndrome Market Industry Trends: What Changes Are Reshaping Demand?

    Within the short bowel syndrome market, leading corporations are dedicated to pioneering medical breakthroughs, including therapies for intestinal failure, aiming to furnish superior therapeutic choices that enhance patient prognoses for those suffering from digestive ailments. Intestinal failure signifies a severe state wherein the small intestine fails to absorb adequate sustenance, hydration, and vital minerals, thereby impeding the body’s ability to sustain essential functions. To illustrate, in May of 2024, Ironwood Pharmaceuticals, Inc., a pharmaceutical entity headquartered in the United States, presented new research findings pertaining to the investigation of apraglutide in adult patients experiencing short bowel syndrome accompanied by intestinal failure (SBS-IF). This investigational agent, classified as a novel GLP-2 analog, has shown promise in improving the gut’s ability to absorb nutrients and diminishing the need for intravenous feeding. Such results highlight the therapeutic’s effectiveness, safety profile, and sustained advantages, mirroring Ironwood’s dedication to creating groundbreaking treatments for intestinal conditions.

    Short Bowel Syndrome Market Key Players And Strategic Industry Positioning

    Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co Ltd, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc, OxThera Inc, EnteraBio Ltd, GLyPharma Therapeutic Inc, Fresenius Kabi AG, Danone S A, B Braun Melsungen AG, Medtronic plc

    Access The Complete Short Bowel Syndrome Market Report:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    Short Bowel Syndrome Market Geographic Analysis: Where Is Demand Growing The Fastest?

    North Americawas the largest region in the short bowel syndrome market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Short Bowel Syndrome Market Growth Forecast With Analysis Of Industry Progress Through 2030

    Short Bowel Syndrome Market Growth Forecast With Analysis Of Industry Progress Through 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Is The Forecasted Rise In Market Size Of The Short Bowel Syndrome Market During The Forecast Period?

    The market size for short bowel syndrome has experienced rapid expansion in recent years. It is forecast to rise from $3.08 billion in 2025 to $3.53 billion in 2026, at a compound annual growth rate (CAGR) of 14.6%. This historical growth stemmed from various factors, including the increasing prevalence of short bowel syndrome, historically limited treatment options, reliance on parenteral nutrition, a rise in gastrointestinal surgeries, and growing hospital awareness.

    The market size for short bowel syndrome is poised for substantial expansion over the upcoming years. It is projected to reach $6.02 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. This growth during the forecast period can be attributed to factors such as the development of innovative therapeutics, enhanced accessibility to home infusion services, the implementation of personalized treatment approaches, the integration of microbiome therapies, and an increase in clinical trials for SBS interventions. Significant trends expected in the forecast period encompass a rise in parenteral nutrition solutions, intensified development of intestinal rehabilitation therapies, the adoption of new surgical interventions, a heightened focus on gut microbiome modulation, and the expansion of patient support programs.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    What Important Drivers Are Powering The Short Bowel Syndrome Market Growth?

    The rising occurrence of gastrointestinal diseases is expected to drive the growth of the short bowel syndrome market in the future. Gastrointestinal diseases encompass a wide array of conditions impacting the digestive system, including disorders affecting the stomach, intestines, liver, and pancreas, often leading to compromised digestion and nutrient absorption. The expanding prevalence of gastrointestinal diseases is primarily fueled by unhealthy dietary patterns that disrupt gut health and promote inflammation. These diseases can contribute to the development of short bowel syndrome by necessitating the surgical removal of damaged intestinal segments, which results in reduced absorptive capacity. For example, in September 2023, data from the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization focused on improving the lives of patients with Crohn’s disease and ulcerative colitis, indicated that over 320,000 people in Canada have inflammatory bowel disease (IBD), with a prevalence of 825 per 100,000 in 2023. As the prevalence is projected to increase by 2.44% annually, it is estimated that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Thus, the increasing prevalence of gastrointestinal diseases is a significant driver for the short bowel syndrome market’s expansion.

    What Key Segment Areas Are Included In The Short Bowel Syndrome Market Assessment?

    The short bowel syndrome market covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

    2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

    3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

    4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine, Intravenous Glutamine

    Which Trends Are Expected To Shape The Short Bowel Syndrome Market?

    Leading companies within the sexually transmitted infections (STIs) market are creating advanced products utilizing fluorescent PCR technology to secure a competitive edge. Fluorescent PCR (Polymerase Chain Reaction) technology, a molecular biology technique, is employed for the detection and quantification of particular DNA sequences within biological samples. As an example, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a Chinese molecular diagnostic solutions provider, launched two new polymer chain reaction (PCR) kits: the Mycoplasma Hominis Real-Time PCR Kit and the Treponema Pallidum Real-Time PCR Kit. These kits offer a comprehensive PCR solution for the early identification of sexually transmitted illnesses, which affect a significant number of people. The BioPerfectus Mycoplasma Hominis Real-Time PCR Kit is a reagent designed to detect Mycoplasma hominis in human male urethral swabs, female cervical or vaginal swabs, and urine samples using fluorescent PCR technology. Conversely, the BioPerfectus Treponema Pallidum Real-Time PCR Kit aims to identify treponema pallidum nucleic acid in human serum and plasma.

    Which Firms Are Competing In The Short Bowel Syndrome Market?

    Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co Ltd, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc, OxThera Inc, EnteraBio Ltd, GLyPharma Therapeutic Inc, Fresenius Kabi AG, Danone S A, B Braun Melsungen AG, Medtronic plc

    Access The Complete Short Bowel Syndrome Market Report:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    Which Region Stands As The Largest Contributor To The Short Bowel Syndrome Market?

    North America was the largest region in the short bowel syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access Short Bowel Syndrome Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

    Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2026, By The Business Research Company

    Bowel Management Systems Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

    Inflammatory Bowel Disease Treatment Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

    Ulcerative Colitis Global Market Report 2026

    https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Short bowel syndrome market to approach $6.01 billion by 2030

    Short bowel syndrome market to approach $6.01 billion by 2030

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    From Its 2026 Market Size, What Value Is The Short Bowel Syndrome Market Projected To Reach By 2030?

    The market for short bowel syndrome has seen rapid expansion in recent years. It is anticipated to expand from $3.08 billion in 2025 to $3.53 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.6%. The factors contributing to this growth historically include the increasing prevalence of short bowel syndrome, the limited treatment options available in the past, the reliance on parenteral nutrition, a rise in gastrointestinal surgeries, and growing hospital awareness.

    The market for short bowel syndrome is projected to experience swift expansion in the coming years, anticipated to reach a valuation of $6.02 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. Key factors driving this growth during the forecast period include the creation of new therapeutic options, wider access to home infusion services, individualized treatment strategies, the incorporation of microbiome-based therapies, and a rise in clinical trials for SBS treatments. Significant trends expected in the forecast period encompass an increase in parenteral nutrition solutions, the ongoing development of therapies for intestinal rehabilitation, the implementation of innovative surgical procedures, an amplified focus on modulating the gut microbiome, and the broadening of patient support initiatives.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    What Major Factors Are Driving The Short Bowel Syndrome Market Forward?

    The rising incidence of gastrointestinal conditions is anticipated to fuel expansion in the short bowel syndrome market in the coming period. These illnesses encompass a wide spectrum of ailments impacting the digestive system, such as those affecting the stomach, intestines, liver, and pancreas, frequently resulting in hindered digestion and diminished nutrient uptake. The escalating occurrence of gastrointestinal disorders is primarily fueled by poor dietary choices that compromise gut well-being and encourage inflammation. Gastrointestinal ailments can lead to the emergence of short bowel syndrome, often requiring the surgical excision of impaired intestinal parts, which in turn diminishes the body’s capacity for absorption. As an illustration, data from September 2023 provided by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian organization dedicated to enhancing the lives of individuals with Crohn’s disease and ulcerative colitis, revealed that in 2023, over 320,000 people in Canada were living with inflammatory bowel disease (IBD), exhibiting a prevalence of 825 per 100,000. With an anticipated annual increase in prevalence of 2.44%, projections indicate that 1.1% of the Canadian population, equating to 470,000 individuals, will be affected by IBD by 2035. Consequently, the rising occurrence of gastrointestinal diseases is a key factor propelling the expansion of the short bowel syndrome market.

    Which Segments Define The Short Bowel Syndrome Market Segment Structure?

    The short bowel syndrome market covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

    2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

    3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

    4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine, Intravenous Glutamine

    Which Trends Are Impacting The Progress Of The Short Bowel Syndrome Market?

    Leading companies in the short bowel syndrome market are concentrating on advancing medical science through innovations like treatments for intestinal failure, aiming to provide an enhanced therapeutic option that improves patient outcomes for those with gastrointestinal disorders. Intestinal failure represents a severe condition where the small intestine cannot adequately absorb nutrients, fluids, and electrolytes crucial for maintaining proper hydration and nutrition. For instance, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare entity, disclosed new data from studies evaluating apraglutide in adults diagnosed with short bowel syndrome and intestinal failure (SBS-IF). As a next-generation GLP-2 analog, apraglutide exhibited potential to improve intestinal absorption and lessen dependence on parenteral support. These results emphasize the drug’s effectiveness, safety, and sustained advantages, reflecting Ironwood’s dedication to developing inventive treatments for gastrointestinal conditions.

    Who Are The Established Players Within The Short Bowel Syndrome Market?

    Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co Ltd, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc, OxThera Inc, EnteraBio Ltd, GLyPharma Therapeutic Inc, Fresenius Kabi AG, Danone S A, B Braun Melsungen AG, Medtronic plc

    Get The Full Short Bowel Syndrome Market Report:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    Which Region Is The Largest In The Short Bowel Syndrome Market?

    North America was the largest region in the short bowel syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Short Bowel Syndrome Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2026, By The Business Research Company

    Bowel Management Systems Market Report 2026

    https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

    Inflammatory Bowel Disease Treatment Market Report

    https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

    Ulcerative Colitis Market Report

    https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Short Bowel Syndrome Industry Trends and Market Growth Forecast for 2026–2030

    Global Short Bowel Syndrome Industry Trends and Market Growth Forecast for 2026–2030

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Is The Market Size Of The Short Bowel Syndrome Market Expected To Change Between 2026 And 2030?

    The market size for short bowel syndrome has experienced rapid expansion in recent years. It is projected to increase from $3.08 billion in 2025 to $3.53 billion by 2026, showing a compound annual growth rate (CAGR) of 14.6%. The expansion observed in the historic period can be attributed to factors such as the increasing prevalence of short bowel syndrome, historically limited treatment options, a reliance on parenteral nutrition, a rise in gastrointestinal surgeries, and growing awareness within hospitals.

    The short bowel syndrome market size is anticipated to experience substantial growth over the coming years, with projections indicating it will reach $6.02 billion by 2030, expanding at a compound annual growth rate (CAGR) of 14.2%. This expected increase during the forecast period is primarily driven by the introduction of novel therapeutics, improved access to home infusion services, the emergence of personalized treatment approaches, the integration of microbiome therapies, and a rise in clinical trials for SBS interventions. Significant trends identified for this period encompass an increase in parenteral nutrition solutions, the ongoing development of intestinal rehabilitation therapies, the adoption of innovative surgical interventions, a heightened focus on gut microbiome modulation, and the expansion of patient support programs.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    What Underlying Factors Are Accelerating The Growth Of The Short Bowel Syndrome Market?

    The rising incidence of gastrointestinal ailments is anticipated to drive expansion within the short bowel syndrome market in the future. Gastrointestinal diseases encompass a broad spectrum of conditions impacting the digestive tract, including disorders affecting the stomach, intestines, liver, and pancreas, frequently leading to impaired digestion and nutrient absorption. The increasing occurrence of these diseases is largely fueled by unhealthy dietary habits that disrupt gut health and foster inflammation. Gastrointestinal conditions can contribute to the development of short bowel syndrome by necessitating the surgical removal of damaged intestinal segments, resulting in reduced absorptive capacity. For example, in September 2023, information from the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization focused on enhancing the lives of patients with Crohn’s disease and ulcerative colitis, indicated that over 320,000 people in Canada suffer from inflammatory bowel disease (IBD), with a prevalence of 825 per 100,000 in 2023. As the prevalence is expected to increase by 2.44% annually, projections suggest that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Therefore, the growing prevalence of gastrointestinal diseases is stimulating the growth of the short bowel syndrome market.

    How Is The Short Bowel Syndrome Market Structured Across Different Segments?

    The short bowel syndrome market covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

    2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

    3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

    4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine, Intravenous Glutamine

    What Major Market Trends Are Driving Changes In The Short Bowel Syndrome Market?

    Companies active in the short bowel syndrome market are concentrating on creating pioneering advancements in medical science, such as therapies for intestinal failure, to deliver an enhanced therapeutic choice that improves patient outcomes for those with gastrointestinal disorders. Intestinal failure is a severe condition where the small intestine cannot adequately absorb enough nutrients, fluids, and electrolytes essential for maintaining proper hydration and nutrition. For instance, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare company, disclosed new data from studies evaluating apraglutide in adults with short bowel syndrome and intestinal failure (SBS-IF). As a next-generation GLP-2 analog, apraglutide exhibited potential to augment intestinal absorption and lessen the dependence on parenteral support. The findings emphasize the drug’s efficacy, safety, and long-term benefits, reflecting Ironwood’s commitment to advancing innovative therapies for gastrointestinal disorders.

    Which Major Players Dominate The Short Bowel Syndrome Market?

    Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co Ltd, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc, OxThera Inc, EnteraBio Ltd, GLyPharma Therapeutic Inc, Fresenius Kabi AG, Danone S A, B Braun Melsungen AG, Medtronic plc

    Read the full short bowel syndrome market report here:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    Which Region Is Projected To Dominate The Short Bowel Syndrome Market During The Forecast Period?

    North America was the largest region in the short bowel syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Short Bowel Syndrome Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

    Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2026, By The Business Research Company

    Bowel Management Systems Global Market Report

    https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

    Inflammatory Bowel Disease Treatment Global Market Report

    https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

    Ulcerative Colitis Global Market Report

    https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Short Bowel Syndrome Market Trends and Insights: Global Forecast to 2030

    Short Bowel Syndrome Market Trends and Insights: Global Forecast to 2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the short bowel syndrome market from 2026–2035 with trusted insights from The Business Research Company

    What long-term size projections exist for the Short Bowel Syndrome Market covering 2026–2035?

    The market size for short bowel syndrome has experienced rapid growth in recent years. It is projected to expand from $3.08 billion in 2025 to $3.53 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.6%. The market’s historic growth can be attributed to factors such as the increasing prevalence of short bowel syndrome, the historically limited treatment options available, a reliance on parenteral nutrition, a rise in gastrointestinal surgeries, and growing hospital awareness.

    The market size for short bowel syndrome is projected to experience rapid expansion in the next few years, reaching $6.02 billion by 2030 at a compound annual growth rate (CAGR) of 14.2%. This growth over the forecast period is attributable to the development of novel therapeutics, increasing availability of home infusion services, personalized treatment approaches, the integration of microbiome therapies, and a rise in clinical trials for SBS interventions. Major trends expected during this period include an increase in parenteral nutrition solutions, the advancing development of intestinal rehabilitation therapies, the adoption of novel surgical interventions, a growing emphasis on gut microbiome modulation, and the expansion of patient support programs.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    Which Drivers Are Impacting The Competitive Landscape Of The Short Bowel Syndrome Market?

    The rising occurrence of gastrointestinal diseases is anticipated to drive the expansion of the short bowel syndrome market in the coming years. Gastrointestinal diseases refer to a broad category of conditions that affect the digestive tract, encompassing disorders of the stomach, intestines, liver, and pancreas, often leading to compromised digestion and nutrient absorption. The increasing incidence of these diseases is primarily fueled by unhealthy dietary habits that negatively impact gut health and promote inflammation. Such gastrointestinal conditions can contribute to the development of short bowel syndrome by necessitating the surgical removal of damaged intestinal segments, which results in a diminished absorptive capacity. For instance, in September 2023, data from the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization dedicated to improving the lives of patients with Crohn’s disease and ulcerative colitis, revealed that in 2023, over 320,000 people in Canada suffered from inflammatory bowel disease (IBD), with a prevalence of 825 per 100,000. Given that the prevalence is projected to increase by 2.44% annually, it is estimated that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Consequently, the increasing prevalence of gastrointestinal diseases is propelling the growth of the short bowel syndrome market.

    What Segments Are Identified Within The Structure Of The Short Bowel Syndrome Market?

    The short bowel syndrome market covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

    2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

    3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

    4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine, Intravenous Glutamine

    Which Innovation Trends Are Advancing Developments Within The Short Bowel Syndrome Market?

    Leading companies in the short bowel syndrome market are prioritizing the creation of innovative medical advancements, such as therapies for intestinal failure, to offer an advanced treatment option that improves patient outcomes for those with gastrointestinal disorders. Intestinal failure is a severe condition where the small intestine is unable to absorb sufficient nutrients, fluids, and electrolytes to maintain adequate hydration and nutrition. For instance, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare company, released new data from studies evaluating apraglutide in adults with short bowel syndrome and intestinal failure (SBS-IF). As a next-generation GLP-2 analog, apraglutide exhibited potential to improve intestinal absorption and lessen the dependence on parenteral support. These findings emphasize the drug’s efficacy, safety, and long-term advantages, reflecting Ironwood’s dedication to developing novel treatments for gastrointestinal disorders.

    Which Major Firms Are Strengthening Their Position In The Short Bowel Syndrome Market?

    Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co Ltd, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc, OxThera Inc, EnteraBio Ltd, GLyPharma Therapeutic Inc, Fresenius Kabi AG, Danone S A, B Braun Melsungen AG, Medtronic plc

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    Which Region Is Anticipated To See The Fastest Growth In The Short Bowel Syndrome Market?

    North America was the largest region in the short bowel syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Short Bowel Syndrome Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

    Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2026, By The Business Research Company

    Ulcerative Colitis Market Report 2026

    https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

    Bowel Management Systems Market Report 2026

    https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

    Inflammatory Bowel Disease Treatment Market Report 2026

    https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • How Is The Short Bowel Syndrome Market Expected To Grow At 14.4% CAGR Over 2025–2029?

    How Is The Short Bowel Syndrome Market Expected To Grow At 14.4% CAGR Over 2025–2029?

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    How Much Will The Short Bowel Syndrome Market Be Worth By 2029?

    There has been a significant expansion in the market size for short bowel syndrome over the past few years. The market, which is projected to rise from $2.69 billion in 2024 to $3.08 billion in 2025, is anticipated to have a compound annual growth rate (CAGR) of 14.6%. Factors contributing to this growth during the historic period include heightened instances of gastrointestinal complications, escalated expenditures on healthcare and insurance coverage, advancements in the post-operative care of SBS, rise in the incidence of Crohn’s disease and other GI complications, and upgrades in parenteral nutrition formulations and application methods.

    In the upcoming years, the short bowel syndrome market is anticipated to witness substantial growth, expanding to $5.29 billion in 2029 with a CAGR of 14.4%. The escalation during the forecast period can be credited to factors such as the increasing incidence of short bowel syndrome (SBS), the rising uptake of parenteral and enteral nutrition therapy, the development of clinical research and medicinal studies, escalating health care expenditure, and the growth in awareness and premature diagnosis of SBS. Key trends during the forecast period are expected to be improvements in intestinal rehabilitation treatments, advancements in small intestine transplant procedures, the utilization of telemedicine for managing SBS, technological progress in enteral feeding devices, and the incorporation of artificial intelligence in planning SBS treatment.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    What External And Internal Drivers Are Influencing The Short Bowel Syndrome Market?

    The anticipated ascent in the occurrence of gastrointestinal disorders is predicted to spur expansion of the short bowel syndrome industry. These disorders feature a range of issues influencing the digestive system, such as conditions affecting the stomach, intestines, liver and pancreas, which often lead to dysfunction in digestion and the absorption of nutrients. Unhealthy diet habits are primarily responsible for the rising occurrence of gastrointestinal diseases, often damaging gut health and promoting inflammation. This kind of diseases can lead to the onset of short bowel syndrome by necessitating the surgical elimination of damaged intestinal segments, thus reducing absorptive capabilities. For instance, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre in Canada reported in September 2023, that over 320,000 individuals in Canada had IBD, with a prevalence rate of 825 per 100,000. The rate is expected to rise annually by 2.44%, implying that by 2035, 1.1% of the population, or roughly 470,000 Canadians, may be living with IBD. Therefore, the escalating occurrence of gastrointestinal diseases promotes the growth of the short bowel syndrome market.

    What Segmentation Insights Are Provided In The Short Bowel Syndrome Market Research?

    The short bowel syndromemarket covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine

    2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis

    3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant

    4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine; Intravenous Glutamine

    Which Market Trends Are Expected To Define The Future Of The Short Bowel Syndrome Market?

    The emphasis of leading corporations in the short bowel syndrome sector is on spurring innovative progress in medical studies, such as therapies for intestinal failure, to offer a sophisticated treatment alternative that bolsters patient outcomes grappling with gastrointestinal maladies. Intestinal failure, a grave condition, occurs when the small intestine fails to absorb adequate nutrients, fluids, and electrolytes, thereby impeding proper hydration and nutrition. For example, American healthcare firm Ironwood Pharmaceuticals, Inc., revealed fresh data from tests assessing apraglutide’s impact on adults with short bowel syndrome and intestinal failure (SBS-IF) in May 2024. As an up-and-coming GLP-2 analog, apraglutide showed the potential to augment intestinal absorption and minimize dependence on parenteral support. The results emphasize the drug’s effectiveness, safety, and lasting benefits, mirroring Ironwood’s dedication to the creation of groundbreaking therapies for gastrointestinal issues.

    Who Are The Leading Companies Driving The Short Bowel Syndrome Market?

    Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc. , Adocia SAS, EnteraBio Ltd, GLyPharma Therapeutic Inc.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    Which Geographic Regions Are Creating Strong Demand In The Short Bowel Syndrome Market?

    North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

    Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2025, By The Business Research Company

    Inflammatory Bowel Disease Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

    Irritable Bowel Syndrome Ibs Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

    Cough Hypersensitivity Syndrome Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cough-hypersensitivity-syndrome-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Short Bowel Syndrome Market Size and Growth Forecast for Businesses 2025–2029

    Short Bowel Syndrome Market Size and Growth Forecast for Businesses 2025–2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    #What Are The Current (2025) And Forecast (2029) Sizes Of The Short Bowel Syndrome Market?

    The short bowel syndrome market size has seen rapid expansion in recent years. It is anticipated to increase from $2.69 billion in 2024 to $3.08 billion in 2025, achieving a compound annual growth rate (CAGR) of 14.6%. The historical growth of this market can be attributed to several factors including the rising prevalence of gastrointestinal disorders, increasing healthcare expenditure and insurance coverage, enhancements in the post-surgical management of SBS, an uptick in the prevalence of Crohn’s disease and other GI disorders, and improved parenteral nutrition formulations and administration techniques.

    The market for short bowel syndrome is projected to experience swift expansion over the coming years. This market is anticipated to reach $5.29 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.4%. This projected growth is primarily driven by factors such as the increasing incidence of short bowel syndrome (SBS), wider acceptance of parenteral and enteral nutrition therapies, advancements in clinical research and drug discovery, greater healthcare spending, and improved public awareness leading to earlier diagnosis of SBS. Key trends expected during this period involve enhancements in intestinal rehabilitation treatments, the evolution of small intestine transplantation methods, the utilization of telemedicine for managing SBS, innovations in enteral feeding device technology, and the incorporation of artificial intelligence into SBS treatment strategies.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    Which Industry Drivers Are Expected To Accelerate The Short Bowel Syndrome Market From 2025 To 2029?

    The short bowel syndrome market is anticipated to expand due to the rising occurrence of gastrointestinal illnesses. Gastrointestinal diseases encompass various conditions affecting the digestive system, such as those impacting the stomach, intestines, liver, and pancreas, frequently resulting in poor digestion and nutrient uptake. Unhealthy eating patterns, which negatively affect gut health and trigger inflammation, are a major contributor to the increasing incidence of gastrointestinal diseases. These diseases can lead to short bowel syndrome when surgical removal of compromised intestinal parts becomes necessary, thereby diminishing the gut’s ability to absorb nutrients. For example, data from September 2023, provided by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian organization focused on enhancing the lives of patients with Crohn’s disease and ulcerative colitis, indicated that in 2023, over 320,000 people in Canada were affected by inflammatory bowel disease (IBD), showing a prevalence of 825 per 100,000. With an anticipated annual increase in prevalence of 2.44%, projections suggest that by 2035, 1.1% of the population, or 470,000 Canadians, will be living with IBD. Consequently, the rising occurrence of gastrointestinal conditions is a key factor propelling the expansion of the short bowel syndrome market.

    What Are The Key Segments In The Short Bowel Syndrome Market?

    The short bowel syndromemarket covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine

    2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis

    3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant

    4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine; Intravenous Glutamine

    Which Ongoing Trends Are Expected To Shape The Short Bowel Syndrome Market Outlook?

    Leading companies in the short bowel syndrome market are prioritizing the development of innovative breakthroughs in medical science, such as therapies for intestinal failure, to offer an advanced treatment choice that enhances results for individuals with gastrointestinal conditions. Intestinal failure is a severe condition where the small intestine cannot adequately absorb enough nutrients, fluids, and electrolytes to maintain proper hydration and nutrition. For instance, in May 2024, Ironwood Pharmaceuticals, Inc., a US healthcare enterprise, presented new data from studies assessing apraglutide in adults with short bowel syndrome and intestinal failure (SBS-IF). As a next-generation GLP-2 analog, apraglutide exhibited the potential to improve intestinal absorption and lessen dependence on parenteral support. These findings underscore the drug’s effectiveness, safety, and long-term advantages, reflecting Ironwood’s dedication to developing innovative treatments for gastrointestinal disorders.

    Who Are The Core Companies Influencing The Short Bowel Syndrome Market Landscape?

    Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc. , Adocia SAS, EnteraBio Ltd, GLyPharma Therapeutic Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    What Are The Key Regional Factors Influencing The Short Bowel Syndrome Market Growth?

    North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Short Bowel Syndrome Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

    Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2025, By The Business Research Company

    Inflammatory Bowel Disease Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

    Irritable Bowel Syndrome Ibs Treatment Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

    Cough Hypersensitivity Syndrome Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/cough-hypersensitivity-syndrome-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Emerging Growth Drivers in the Short Bowel Syndrome Market Landscape: Rising Prevalence Of Gastrointestinal Diseases Fueling The Growth Of The Market Due To Increasing Surgical Interventions And Nutrient Malabsorption

    Emerging Growth Drivers in the Short Bowel Syndrome Market Landscape: Rising Prevalence Of Gastrointestinal Diseases Fueling The Growth Of The Market Due To Increasing Surgical Interventions And Nutrient Malabsorption

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Estimated Market Size of the Short Bowel Syndrome Market In 2029?

    Recent years have witnessed a swift expansion in the market size for short bowel syndrome. The industry is predicted to continue this growth trajectory, escalating from a worth of $2.69 billion in 2024 to approximately $3.08 billion in 2025 – a compound annual growth rate (CAGR) of 14.6%. This advancement during the historic era can be ascribed to factors like a rising incidence of gastrointestinal issues, escalated healthcare expenditure and insurance coverage, enhanced post-operative care for short bowel syndrome patients, an upsurge in the occurrence of Crohn’s disease and other related gastrointestinal disorders, and the upgrades in parenteral nutrition formulas and their administration methods.

    In the coming years, the market size of short bowel syndrome stands to witness accelerated expansion, projected to reach$5.29 billion by the year 2029, growing at a compound annual growth rate (CAGR) of 14.4%. The projected escalation within this timeframe can be linked to the escalation in short bowel syndrome (SBS) cases, the increased usage of parenteral and enteral nutritional therapies, surge in clinical research and pharmaceutical innovation, heightened healthcare spending, and improved early discovery and awareness about SBS. During this period, we anticipate innovations in intestinal rehabilitation therapies, further progress in small intestine transplant methods, the application of telemedicine for managing SBS, advancements in technology for enteral feeding apparatus, and the integration of artificial intelligence in planning SBS treatment to be the prominent trends.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    Which Primay Drivers Are Accelerating Growth in the Short Bowel Syndrome Market?

    The escalating occurrence of gastrointestinal conditions is anticipated to fuel the expansion of the short bowel syndrome market in the future. Gastrointestinal ailments encompass a wide array of disorders impacting the digestive system, which consist of conditions affecting the stomach, intestines, liver, and pancreas often resulting in compromised digestion and nutrient intake. The augmentation in the occurrence of gastrointestinal ailments is primarily influenced by unhealthy eating habits, which disturb gut health and encourage inflammation. These diseases can lead to the development of short bowel syndrome as they may require surgical removal of impaired intestinal segments, causing a reduction in absorption capability. For example, in September 2023, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian organization dedicated to enhancing the lives of patients afflicted with Crohn’s disease and ulcerative colitis, stated that there was a prevalence of 825 per 100,000 in 2023, meaning over 320,000 individuals in Canada suffer from inflammatory bowel disease (IBD). Since the prevalence is projected to rise by 2.44% annually, about 1.1% of the population or approximately 470,000 Canadians are expected to be living with IBD by 2035. Therefore, the escalating occurrence of gastrointestinal conditions is steering the growth of the short bowel syndrome market.

    Which Primary Segments of the Short Bowel Syndrome Market Are Driving Growth and Industry Transformations?

    The short bowel syndromemarket covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine

    2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis

    3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant

    4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine; Intravenous Glutamine

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

    Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Short Bowel Syndrome Market?# Market?

    North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Which Technological Trends Are Reshaping the Short Bowel Syndrome Industry Dynamics?

    Leading businesses in the short bowel syndrome market are honing their focus on pioneering progress in medical science. This includes establishing innovative treatment methods for intestinal failure, which could offer a cutting-edge therapeutic solution designed to optimize treatment results for patients suffering from gastrointestinal disorders. In this context, intestinal failure is a severe disorder where the individual’s small intestine fails to sufficiently absorb nutrients, fluids, and electrolytes to sustain adequate hydration and nutrition. For example, in May 2024, Ironwood Pharmaceuticals, Inc., a renowned healthcare company based in the US, disclosed new research data linked to the evaluation of apraglutide in adults diagnosed with short bowel syndrome and intestinal failure (SBS-IF). Apraglutide, a cutting-edge GLP-2 analog, showed potential in improving intestinal absorption and lessening dependence on parenteral support. This research underlines the efficacy, safety, and lasting benefits of the drug, showcasing Ironwood’s commitment to the development of innovative treatments for gastrointestinal disorders.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    What Parameters Are Used to Define the Short Bowel Syndrome Market?

    Short bowel syndrome (SBS) is a malabsorption disorder caused by the loss or dysfunction of a significant portion of the small intestine, leading to impaired nutrient and fluid absorption. It often results in diarrhea, dehydration, electrolyte imbalances, and malnutrition. The severity of symptoms depends on the remaining intestinal length and its ability to adapt. SBS can significantly impact overall health, requiring careful dietary and medical management.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23515

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Emerging Growth Drivers in the Short Bowel Syndrome Market Landscape: Rising Prevalence Of Gastrointestinal Diseases Fueling The Growth Of The Market Due To Increasing Surgical Interventions And Nutrient Malabsorption

    Emerging Growth Drivers in the Short Bowel Syndrome Market Landscape: Rising Prevalence Of Gastrointestinal Diseases Fueling The Growth Of The Market Due To Increasing Surgical Interventions And Nutrient Malabsorption

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What Is the Estimated Market Size of the Short Bowel Syndrome Market In 2029?

    Recent years have witnessed a swift expansion in the market size for short bowel syndrome. The industry is predicted to continue this growth trajectory, escalating from a worth of $2.69 billion in 2024 to approximately $3.08 billion in 2025 – a compound annual growth rate (CAGR) of 14.6%. This advancement during the historic era can be ascribed to factors like a rising incidence of gastrointestinal issues, escalated healthcare expenditure and insurance coverage, enhanced post-operative care for short bowel syndrome patients, an upsurge in the occurrence of Crohn’s disease and other related gastrointestinal disorders, and the upgrades in parenteral nutrition formulas and their administration methods.

    In the coming years, the market size of short bowel syndrome stands to witness accelerated expansion, projected to reach$5.29 billion by the year 2029, growing at a compound annual growth rate (CAGR) of 14.4%. The projected escalation within this timeframe can be linked to the escalation in short bowel syndrome (SBS) cases, the increased usage of parenteral and enteral nutritional therapies, surge in clinical research and pharmaceutical innovation, heightened healthcare spending, and improved early discovery and awareness about SBS. During this period, we anticipate innovations in intestinal rehabilitation therapies, further progress in small intestine transplant methods, the application of telemedicine for managing SBS, advancements in technology for enteral feeding apparatus, and the integration of artificial intelligence in planning SBS treatment to be the prominent trends.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    Which Primay Drivers Are Accelerating Growth in the Short Bowel Syndrome Market?

    The escalating occurrence of gastrointestinal conditions is anticipated to fuel the expansion of the short bowel syndrome market in the future. Gastrointestinal ailments encompass a wide array of disorders impacting the digestive system, which consist of conditions affecting the stomach, intestines, liver, and pancreas often resulting in compromised digestion and nutrient intake. The augmentation in the occurrence of gastrointestinal ailments is primarily influenced by unhealthy eating habits, which disturb gut health and encourage inflammation. These diseases can lead to the development of short bowel syndrome as they may require surgical removal of impaired intestinal segments, causing a reduction in absorption capability. For example, in September 2023, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian organization dedicated to enhancing the lives of patients afflicted with Crohn’s disease and ulcerative colitis, stated that there was a prevalence of 825 per 100,000 in 2023, meaning over 320,000 individuals in Canada suffer from inflammatory bowel disease (IBD). Since the prevalence is projected to rise by 2.44% annually, about 1.1% of the population or approximately 470,000 Canadians are expected to be living with IBD by 2035. Therefore, the escalating occurrence of gastrointestinal conditions is steering the growth of the short bowel syndrome market.

    Which Primary Segments of the Short Bowel Syndrome Market Are Driving Growth and Industry Transformations?

    The short bowel syndromemarket covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine

    2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis

    3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant

    4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine; Intravenous Glutamine

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

    Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Short Bowel Syndrome Market?# Market?

    North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Which Technological Trends Are Reshaping the Short Bowel Syndrome Industry Dynamics?

    Leading businesses in the short bowel syndrome market are honing their focus on pioneering progress in medical science. This includes establishing innovative treatment methods for intestinal failure, which could offer a cutting-edge therapeutic solution designed to optimize treatment results for patients suffering from gastrointestinal disorders. In this context, intestinal failure is a severe disorder where the individual’s small intestine fails to sufficiently absorb nutrients, fluids, and electrolytes to sustain adequate hydration and nutrition. For example, in May 2024, Ironwood Pharmaceuticals, Inc., a renowned healthcare company based in the US, disclosed new research data linked to the evaluation of apraglutide in adults diagnosed with short bowel syndrome and intestinal failure (SBS-IF). Apraglutide, a cutting-edge GLP-2 analog, showed potential in improving intestinal absorption and lessening dependence on parenteral support. This research underlines the efficacy, safety, and lasting benefits of the drug, showcasing Ironwood’s commitment to the development of innovative treatments for gastrointestinal disorders.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    What Parameters Are Used to Define the Short Bowel Syndrome Market?

    Short bowel syndrome (SBS) is a malabsorption disorder caused by the loss or dysfunction of a significant portion of the small intestine, leading to impaired nutrient and fluid absorption. It often results in diarrhea, dehydration, electrolyte imbalances, and malnutrition. The severity of symptoms depends on the remaining intestinal length and its ability to adapt. SBS can significantly impact overall health, requiring careful dietary and medical management.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23515

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Short Bowel Syndrome Market Projected at $5.33 Billion by 2029 | Strategic Insights and Forecast Data

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Short Bowel Syndrome Market Size Changed, over the years?

    The market size of short bowel syndrome has seen considerable growth in recent years. Predicted to escalate from $2.69 billion in 2024 to $3.09 billion in 2025, it is expected to have a compound annual growth rate (CAGR) of 14.9%. Factors contributing to the growth during the historic period include an increased prevalence of gastrointestinal disorders, a rise in healthcare spending and insurance coverage, enhancements in the post-operative treatment of SBS, a surge in the prevalence of Crohn’s disease and other GI disorders, and progress in parenteral nutrition formulations and delivery methods.

    How Much Will the Short Bowel Syndrome Market Be Worth in 2029?

    Over the coming years, the market size for short bowel syndrome is projected to experience swift expansion, increasing to $5.33 billion in 2029 with a compound annual growth rate (CAGR) of 14.6%. This market growth over the projected period can be traced back to a heightened incidence of short bowel syndrome (SBS), a trend towards parenteral and enteral nutrition therapy adoption, wider clinical research and drug development, a hike in healthcare spending, and an increase in awareness and early identification of SBS. The forecast period will likely see significant trends such as improvements in intestinal rehabilitation therapies, progression in small intestine transplantation techniques, the integration of telemedicine in SBS management, advanced technology in enteral feeding devices, and the use of artificial intelligence for SBS treatment planning.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

    Which is the Largest Company in the Short Bowel Syndrome Market?

    Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc. , Adocia SAS, EnteraBio Ltd, GLyPharma Therapeutic Inc.

    What Are the Main Market Drivers in the Short Bowel Syndrome Industry?

    As gastrointestinal diseases continue to become more common, the short bowel syndrome market is predicted to expand accordingly. Gastrointestinal diseases encompass a wide range of issues related to the digestive system, including conditions impacting the stomach, intestines, liver, pancreas, often leading to challenges in digestion and nutrient absorption. The rise of such diseases is majorly attributed to unhealthy eating practices that hamper gut health and stimulate inflammation. Gastrointestinal diseases can precipitate short bowel syndrome, as they might necessitate the surgical removal of damaged parts of the intestine, thereby diminishing its absorptive abilities. For example, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian entity focused on bettering the lives of Crohn’s disease and ulcerative colitis patients, stated in September 2023 that with 825 prevalence per 100,000 in 2023, over 320,000 Canadians are living with IBD. As the anticipated yearly increase is 2.44%, it is estimated that by 2035, about 1.1% of the population, or around 470,000 Canadians will be living with IBD. Consequently, the escalating prevalence of gastrointestinal diseases is fueling the expansion of the short bowel syndrome market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

    How Is the Short Bowel Syndrome Market Segments Structured?

    The short bowel syndrome market covered in this report is segmented –

    1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

    2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

    3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

    4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

    Subsegments:

    1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

    2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

    3) By Glutamine: Oral Glutamine, Intravenous Glutamine

    What Strategic Trends Are Transforming the Short Bowel Syndrome Market?

    Key players in the short bowel syndrome sector are directing their strategic focus towards groundbreaking scientific advancements. These include interventions aimed at remedying intestinal failure, which could potentially revolutionize therapy options for patients suffering from gastrointestinal conditions. Intestinal failure is a severe health issue, characterized by the small intestine’s incapacity to absorb sufficient nutrients, fluids, or electrolytes for the body’s hydration and nutritional needs. In a related development, Ironwood Pharmaceuticals, Inc., a healthcare firm from the US, shared new study results in May 2024. The study involved the evaluation of apraglutide in adult patients diagnosed with short bowel syndrome and intestinal failure (SBS-IF). Apraglutide is a next-generation GLP-2 analog touted to potentially boost intestinal absorption and decrease dependency on parenteral support. These findings highlight the drug’s effectiveness, safety, and enduring advantages and reflect Ironwood’s dedication to crafting innovative treatments for gastrointestinal conditions.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

    Which Global Regions Offer the Highest Growth in the Short Bowel Syndrome Market?

    North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23515

    This Report Delivers Insight On:

    1. How big is the short bowel syndrome market, and how is it changing globally?

    2. Who are the major companies in the short bowel syndrome market, and how are they performing?

    3. What are the key opportunities and risks in the short bowel syndrome market right now?

    4. Which products or customer segments are growing the most in the short bowel syndrome market?

    5. What factors are helping or slowing down the growth of the short bowel syndrome market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model